Patient Capital Management is a Baltimore asset manager founded in 2020 by Samantha McLemore, CFA — Bill Miller's long-time co-manager (working together since 2002, running the flagship Opportunity Equity strategy since 2014). Continuing the Miller-school contrarian tradition, it practices "time arbitrage": exploiting behavioral mispricing to concentrate in controversial growth names (tech, healthcare, Bitcoin-related) at deep discounts to intrinsic value. Its site preserves Bill Miller's complete 1995-2022 market letters, alongside ongoing quarterly letters and webinars.
This report covers Patient Capital's fund performance for the week of August 7-14. The fund fell 1.28%, lagging the S&P 500's 0.39% gain. The manager's view is that the market is very picky: companies that beat earnings and raise guidance get rewarded (e.g., Seadrill up 11%), while those that merely meet expectations get punished (e.g., QXO down 10%). Key holdings mentioned: Seadrill (beat estimates, raised guidance, stock up), Adyen (revenue beat, Goldman Sachs raised price target, stock up 14%), and Precigen (no positive news, stock down 15%).
Patient Capital’s Opportunity Equity strategy fell 1.28% last week (as of August 14, 2026), underperforming the S&P 500’s 0.39% gain, but remains up 17.04% year-to-date, leading the S&P 500 by approximately 250 basis points. The report highlights the performance and market reactions of several portf
Month: -1.28% vs S&P 500 +0.39%, Year-to-Date: +17.04% vs +14.54%.
| Metric | Fund | Benchmark (S&P 500) |
|---|---|---|
| Last Week (08/07-08/14) | -1.28% | +0.39% |
| Month-to-Date | +3.94% | +4.00% |
| Quarter-to-Date | +6.19% | +3.93% |
| Year-to-Date | +17.04% | +14.54% |
| 1 Year | +33.10% | +21.81% |
| 3 Years | +27.81% | +21.75% |
| 5 Years | +8.15% | +13.36% |
| 10 Years | +14.20% | +15.46% |
| Since Inception (Annualized, since 2000/6/26) | +8.92% | +8.61% |
Contributors:
| Position | Type | Weekly Net Return |
|---|---|---|
| Chime Financial Inc (CHYM) | Stock | +10.0% |
| Adyen N.V. (ADYEN NA) | Stock | +14.4% |
| Seadrill Limited (SDRL) | Stock | +11.0% |
| Royalty Pharma plc (RPRX) | Stock | +3.6% |
| Global Payments Inc. (GPN) | Stock | +8.0% |
Detractors:
| Position | Type | Weekly Net Return |
|---|---|---|
| Precigen, Inc. Warrants 2034 | Derivative | -17.6% |
| Precigen, Inc. (PGEN) | Stock | -15.6% |
| QXO, Inc. (QXO) | Stock | -10.2% |
| Amazon.com, Inc. (AMZN) | Stock | -4.3% |
| Broadcom Inc. (AVGO) | Stock | -8.1% |
Stance [Cautious Neutral]. The report does not make a definitive judgment on the macro market but conveys a core view through individual stock cases: The market gives positive feedback to companies that beat expectations and raise guidance (e.g., Seadrill), while reacting weakly to companies that merely meet expectations (e.g., QXO), highlighting investors' high sensitivity to growth prospects in the current environment. The report does not disclose position structure data such as net exposure, leverage, or long/short ratios.
The report does not disclose any new positions, additions, reductions, or liquidations. All discussion revolves around the performance and market reaction of existing holdings, with no information on capital movement at the sector, theme, or geographic level.